Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AVAnavex Life Sciences Corp. logo

Anavex Life Sciences Corp. (AVXL)

NASDAQ Global Select · Currency in USD
$1.33 ▼ -0.03 (-2.21%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.29 ▼ -0.04 (-3.01%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.36
Open
$1.34
Day's Range
$1.29 – $1.35
52 Week Range
$1.14 – $8.79
Volume
626,212
Avg. Volume
1,138,800
Market Cap
$123.29M
Beta (5Y Monthly)
1.17
PE Ratio (TTM)
--
EPS (TTM)
-$0.26
Earnings Date
Nov 24, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.00

Profile: Anavex Life Sciences Corp.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
34
CEO
Terrie Kellmeyer
Website
anavex.com

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.

Earnings

Next report: Tue, Nov 24, 2026
EPS estimate -$0.11
DateEst.Actual
Aug 28, 2026-$0.08-$0.03Beat
Aug 25, 2026-$0.08$0.08Beat
Feb 9, 2026-$0.10-$0.06Beat
Nov 25, 2025-$0.13-$0.11Beat
Aug 12, 2025-$0.13-$0.16Miss
May 13, 2025-$0.16-$0.13Beat

Analyst view

Consensus price target
$11.00 ▲ +727.1%
Range $11.00 – $11.00
Rating: Buy
Buy 85% · Hold 15% · Sell 0%

Get free alerts on AVXL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.